Copiktra (duvelisib capsules - Secura Bio) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient meets ONE of the following: (i) Patient has relapsed or refractory disease AND has breast implant-associated anaplastic large cell lymphoma or hepatosplenic T-cell lymphoma; OR (ii) Patient has peripheral T-cell lymphoma

Approval duration

1 year